HarveyMed secures tens of millions in Pre-A funding, with its full-stack technology establishing the company as a rising contender in the global respiratory support sector

The raised funds will be primarily used to accelerate the iteration of HarveyMed's proprietary technologies in the respiratory support sector, expand production capacity, and advance global commercial expansion. The focus will be on promoting the deep market penetration of its portable oxygen concentrators and ventilator products in high-end markets such as Europe and the United States. With the innovative drive of "Intelligent Manufacturing from China," HarveyMed is committed to enabling the world to breathe anew.

Respiratory diseases pose a significant global healthcare challenge. According to statistics, there is a vast patient base worldwide for chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA). In China alone, the number of COPD patients exceeds 100 million. However, diagnosis and treatment rates, as well as the penetration of medical devices, remain significantly lower than in developed countries in Europe and North America. Against the backdrop of an aging population, respiratory support devices have emerged as another highly promising sector, following cardiovascular care.

HarveyMed, as a pioneering explorer in the global field of respiratory support, has keenly identified this "absolute unmet need." Moving away from low-dimensional competition centered on single products, HarveyMed has developed a comprehensive product pipeline covering the entire spectrum of respiratory disease diagnosis and treatment. From pre-hospital emergency transport and in-hospital critical care to home oxygen therapy and sleep management, HarveyMed is committed to providing global patients with higher-quality and more cost-effective respiratory support solutions.

In the field of portable oxygen concentrators (POCs), international giants, represented by Inogen, have long established high market barriers through complex patent networks, hindering the overseas expansion of high-end Chinese domestic medical devices.

HarveyMed has successfully breached this barrier through disruptive innovation in foundational technology. Leveraging its fully self-developed sensorless FOC (Field-Oriented Control) algorithm and intelligent flow compensation technology, HarveyMed has not only achieved closed-loop control of oxygen output but also ingeniously circumvented Inogen's patent restrictions on molecular sieve arrangement through structural innovation.

This technological breakthrough has gained international recognition. In December 2025, the V-series portable oxygen concentrators independently developed by HarveyMed (covering models V5, V5C, V6, and V6C) officially received U.S. FDA 510(k) certification. The FDA approval not only verifies that HarveyMed's products meet top international standards in electrical safety, electromagnetic compatibility, biocompatibility, and performance metrics but also signifies that China's high-end respiratory equipment now possesses the robust capability to compete head-to-head with leading global brands.

Beyond its breakthroughs in oxygen concentrators, HarveyMed has also demonstrated profound technological expertise in the field of ventilation therapy: